Divisive Devices or UFC 510(k): FDA Meets IOM

In a previous post, I discussed the FDA’s Center for Devices and Radiological Health (CDRH) re-evaluation of the 510(k) review process for medical devices.  This re-evaluation, spearheaded by the very visible director of CDRH, Dr. Jeffrey Shuren, was prompted by industry complaints about the review process, arguments over the safety of cleared devices, and a silverscreen-worthy saga resulting in the bankruptcy of a medical device firm and the ousting of the previous CDRH head.  The re-evaluation process included both an extensive internal review by CDRH itself and an independent review by an Institutes of Medicine (IOM) committee composed of former FDA personnel, physicians, professors of law, an expert on information technology, and an insurance industry representative.  The internal review has been an ongoing effort but the external review culminated in last Friday’s much-anticipated official release of the IOM committee’s report titled “Medical Devices and the Public’s Health: The FDA 510(k) Clearance Process at 35 Years.” Continue reading

Posted in Clinical Trials, FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , | 1 Comment

New FDA Guidances Released in July 2011

:Original raster version: :Image:Food and Drug...

Image via Wikipedia

Here’s a list of the guidances released by FDA in July 2011, compiled by Cato Research Regulatory Scientist Cathy Anderson.

Posted in FDA | Tagged , , , , | Comments Off

Imaginary patients, Imaginary data, et Cetero, et Cetero…

Cetero Research

Image via www.cetero.com

The FDA recently issued a letter to a CRO based in Cary, NC, outlining serious violations at one of their facilities including “widespread falsification of dates and times in laboratory records… and the apparent manipulation of equilibration samples to meet predetermined acceptance criteria.”  This letter is a follow-up to two on-site audits, conducted as a result of a whistleblower complaint, in December 2010 and May 2011 that each resulted in a 483.  Basically, the FDA feels that the CRO’s response to the allegations is inadequate and suggests that the data from multiple studies is irrevocably tainted.  Not only will this cost the sponsors of those trials significant time and money, there are cases where negligence or misconduct could impact patient safety. Continue reading

Posted in Clinical Trials, FDA, Industry News | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off

Choose Canada for Your Next Clinical Trial

CanadaCanadaCanadaWhen it comes to the state of the life science industry in Canada, the critics are numerous.  The past two to three years have been difficult and those that lie ahead are still quite uncertain.  With the growing competition at various levels from emerging countries, it is crucial to not only assess our weaknesses but also to remind ourselves of our strengths.  For Canada, one of its key strengths remains its clinical research environment.

Although innovation and capital are in limited supply, the clinical research environment that Canada offers remains desirable.  Second only to the U.S in 2009 for number of clinical trials hosted, and to France for the cost of conducting clinical trials amongst G7 countries, Canada is a location of choice for the conduct of clinical trials. Continue reading

Posted in Clinical Trials, Health Canada | Tagged , , , , , , , , , | Comments Off

New Guidances from FDA – June 2011

GuidanceHere’s a list of the guidances released by FDA in June 2011, compiled by Cato Research Regulatory Scientist Cathy Anderson.

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , | Comments Off